It is shown that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival in ICB-treated NSCLC patients, and further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients is supported.
J. Guégan, B. Bonhomme, F. Peyraud et al.· Signal Transduction and Targ...· 0 citations
BACKGROUND
Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...
F. Pecci, Xinan Wang, Valentina Santo et al.· Journal of Thoracic Oncology· 0 citations
A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
N. Florez, S. Patel, R. Salgia et al.· Cancer· 1 citation
A deeper understanding of the brain metastatic ecosystem may enable the development of more effective, biology-driven therapeutic approaches for NSCLC BM.
Marcel Kemper, Lea Reitnauer, A. Leonetti et al.· Cancer Biome and Targeted Th...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.